| SAN MATEO, Calif., March 28, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced results from its recently completed Phase 1 clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure. Nile is developing cenderitide as a 90-day outpatient treatment f...continued NLTX Healthcare Drugs |
Wednesday, March 28, 2012
Nile Therapeutics Announces Positive Clinical Trial Results Evaluating the Subcutaneous Infusion of Cenderitide
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment